Genetically engineered TCR-T lead to target solid tumors
Zelluna Immunotherapy presented data on its lead compound ZI-H04 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
12 Nov 2019Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, presented data on its lead TCR compound, ZI-H04 at a poster session during the Annual Meeting of SITC 2019.
Jens-Peter Marschner, Chief Medical Officer, Zelluna Immunotherapy delivered the poster presentation on ZI-H04, Zelluna’s lead candidate. The poster was entitled “ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumors”.
ZI-H04 is an autologous, genetically engineered TCR-T, designed to target solid tumors with large patient populations. It will enter clinical development in autumn 2020. The details on ZI-H04 Jens-Peter included the scientific background of the product, the non-clinical rationale and the clinical design of the phase I/II study.
Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>